The Limbic

Long-term follow-up of the phase 3 Vivacity-MG3 trial has shown nipocalimab’s benefits in antibody-positive generalised myasthenia gravis (gMG) are sustained over time, researchers told the European Academy of Neurology 2026 Congress. Post-hoc analyses also showed symptom improvements held up even when patients caught common infections, offering reassurance about using the monoclonal antibody during periods when disease exacerbations are more likely.

The first comprehensive, evidence-based guidance on the pharmacological options for migraine have been presented at the 2026 European Academy of Neurology (EAN) congress. The guidelines, developed by the International Headache Society and the Italian Society for the Study of Headache, and published in Cephalalgia [link here], offer recommendations for the prevention and acute treatment of migraine, based on a systematic review of all pharmacological therapies.

De-escalating vincristine maintenance therapy can reduce neuropathy in children with acute lymphoblastic leukaemia, a first-of-its-kind study suggests. The researchers conducted a sub-study of the randomised phase 3 UKALL 2011 trial, looking at the trajectory of vincristine-induced peripheral neuropathy (VIPN), a “common but incompletely characterised” complication of childhood ALL treatment, they said.

The YEARS algorithm can rule out pulmonary embolism (PE) when applied to patients with cancer, reducing the need for CT pulmonary angiography in 22% of patients. The findings, from a study published in JAMA and presented at the International Society on Thrombosis and Haemostasis (ISTH) 2026 Congress, provides a path forward to reducing the costs, length of ED stay, and exposure to ionizing radiation and contrast associated with CT pulmonary angiography (CTPA).

After thirteen years, the British Thoracic Society’s Interstitial Lung Disease Registry has closed and is no longer collecting data. The registry’s latest annual report [available here] highlights its achievements in 2025, including 11 new research publications using its data, three successful applications to access the data for research, and more than 2,000 new cases added.

Asthma control among Australian adults has worsened over the past decade despite years of national efforts to improve asthma management, according to a comparison of two national surveys. A study published in the Medical Journal of Australia [link here] found more adults required urgent asthma-related healthcare in 2021 than in 2012, with researchers pointing to persistent reliance on blue puffers and slow uptake of anti-inflammatory reliever therapy as major contributors.

The Medical Services Advisory is running the ruler over an application to fund NT-proBNP testing under Medicare to help guide the treatment of patients with heart failure.

The American Heart Association has outlined the four types of patients who may benefit from deprescribing of medications for cardiovascular disease, giving clinicians a blueprint for managing the risks while minimising adverse events.

Severe pneumonia may comprise three distinct “pneumotypes” with biological differences that could explain why some patients respond better to treatment and recover faster than others, new study findings suggest. The research by Cambridge University Hospitals in the UK involved patients with severe pneumonia treated in intensive care units. Investigators studied immune cells, inflammatory signals and gene activity from fluid collected from patients’ lungs.

The YEARS algorithm can rule out pulmonary metabolism (PE) when applied to patients with cancer, reducing the need for CT pulmonary angiography in 22% of patients. The findings, from a study published in JAMA and presented at the International Society on Thrombosis and Haemostasis (ISTH) 2026 Congress, provides a path forward to reducing the costs, length of ED stay, and exposure to ionizing radiation and contrast associated with CT pulmonary angiography (CTPA).